EMA accepts LEO Pharma’s MAA for delgocitinib cream in chronic hand eczema

LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment

Collaborative efforts and equitable access to diagnostic prevention needed to end TB: Dr. Mandaviya

Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB

Parexel and Partex collaborate to leverage on AI and Big Data to accelerate drug delivery

Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets

National Medical Library has a pivotal role to play in making medical education accessible to all via digital platform: Dr Pawar

Continuous learning is not just an option but a responsibility that every healthcare professional must shoulder

USFDA accepts biologics license application for GC Biopharma's GC5107B

Moderna announces regulatory submissions for its RSV vaccine

The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia

GE HealthCare partners with Elekta to expand access to precision radiation therapy solutions in India

Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy

Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030

Intent to start at least 5 innovative Phase 3 vaccine programs by 2025

Meissa Vaccines enters into CGMP manufacturing agreement for pediatric RSV vaccine candidate for Phase 2 clinical trials

Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials

GSK receives USFDA Fast Track designation for investigational vaccine against gonorrhoea

Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing